There are only a few studies that provide the survival data and analysis of third‐generation targeted drugs in T790M‐negative patients with EGFR‐mutated non‐small cell lung cancer (NSCLC) after progression on first‐ or second‐generation EGFR‐TKIs treatment. Here, EGFR is linked to lung cancer.